- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 03.07. | United Therapeutics pays $140M for thymic cell therapy startup | ||
| 03.07. | AstraZeneca pens $1.7B kidney drug discovery pact with go-to Chinese partner CSPC | ||
| 02.07. | Fosun pays $32M to join Lilly and Novartis in fiercely competitive psoriasis market | ||
| 02.07. | Roche orchestrates phase 3 KRAS lung cancer win over Amgen, BMS | ||
| 01.07. | Merck halts ph. 2 Alzheimer's trial after Neuphoria small molecule underwhelms | ||
| 01.07. | Ipsen gets the Memo, penning €700M deal to buy rare disease biotech for clinical-stage asset | ||
| 01.07. | Backed by top-tier VCs, stealthy biotech bags AlzeCure Alzheimer's asset in $2.2B deal | ||
| 30.06. | Bain-backed bone specialist Angitia drops lead spinal fusion candidate | ||
| 30.06. | FDA gene therapy regulator Vijay Kumar steps down from leadership role | ||
| 30.06. | Abivax rebounds from stock drop with safety data for much-hyped colitis prospect | ||
| 30.06. | Vistagen fails another phase 3 social anxiety trial but spies path to market | ||
| 30.06. | Deerfield's Boulevard Bio pens $1.6B deal for trispecific TCE from China's Metis TechBio | ||
| 30.06. | Praxis faces FDA decision delay as analysts point finger at agency layoffs | ||
| 29.06. | BioCryst ends internal discovery programs, closes Alabama facility in pivot to cost-saving partnerships | ||
| 29.06. | Evommune's phase 2b trial flops, ending challenge to Novartis in hives | ||
| 29.06. | UK-based Scancell bids to buy Nasdaq-listed Neuphoria to 'increase profile' with US investors | ||
| 29.06. | Ipsen pens $1.7B deal to acquire Kartos for potential Jakafi add-on therapy for myelofibrosis | ||
| 29.06. | AstraZeneca unveils phase 3 bone disease data behind $5B forecast for Strensiq successor | ||
| 27.06. | Cash-strapped Alopexx reignites plans to go public via $30M IPO to fund infectious disease programs | ||
| 26.06. | Epicrispr gene silencer is 1st drug to boost muscle in form of muscular dystrophy, biotech says | ||
| 26.06. | Biogen ends Apellis research programs, cuts 'small number' of roles after $5.6B buyout | ||
| 26.06. | Moderna enters in vivo CAR-T, granting autoimmune asset '007' license to kill pathogenic cells | ||
| 25.06. | Otsuka posts phase 3b ADHD trial win ahead of looming FDA approval decision | ||
| 25.06. | Ionis bags $30M from Recordati for ex-US rights to near-approval rare disease prospect | ||
| 24.06. | Spurned by FDA, Passage Bio finds exit through merger with Remix Therapeutics |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.